ArticleAnnals of behavioral medicine : a publication of the Society of Behavioral Medicine2025
Exposure to intimate partner violence and subsequent substance use among a nationwide sample of LGBTQIA+ people: results of The PRIDE Study.
Article in Annals of behavioral medicine : a publication of the Society of Behavioral Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIndividuals who are lesbian, gay, bisexual, transgender, queer or questioning, intersex, aromantic, asexual, or another sexual or gender minority (LGBTQIA+) are at greater risk of both intimate partner violence (IPV) and substance use compared to their cisgender, heterosexual counterparts. However, knowledge regarding the complex relationship between IPV and substance use in LGBTQIA+ communities is limited.
methodsThis study used data from 2 years of The PRIDE (Population Research in Identity and Disparities for Equality) Study, a nationwide, community-based sample of LGBTQIA+ adults in the United States. Past-year IPV in 2021 was measured using the Extended-Hurt, Insulted, Threaten, Scream scale. Substances used in 2022 were measured via the NIDA-Modified Alcohol, Smoking, and Substance Involvement Screening Test (NM ASSIST). Linear and modified Poisson regression models explored temporal relationships between past-year IPV and prospective substance use.
resultsParticipants (n = 3745) were relatively young (median= 34 years, interquartile range: 27.6-48.5) and represented diverse LGBTQIA+ subcommunities. Approximately one-quarter (23.7%) were cisgender women and 17% were cisgender men. Half (49.2%) were gender minority people. Overall, one-quarter (24.6%) reported exposure to IPV in 2021. In adjusted models, past-year IPV was associated with prospective substance use (risk ratio [RR]: 1.11; 95% CI, 1.03-1.19). Additionally, more frequent IPV was associated with a higher prospective NM ASSIST score for cannabis (B: 0.22; 95% CI, 0.08-0.36), stimulants (B: 0.20; 95% CI, 0.06-0.35), hallucinogens (B: 0.07; 95% CI, 0.02-0.12), and narcotics (B: 0.12; 95% CI, 0.03-0.20).
conclusionsExposure to IPV in 2021 was linked to greater substance use in 2022. Findings underscore the role of IPV in substance use among LGBTQIA+ people. Furthermore, they point to the need for increased IPV screening and referral among LGBTQIA+ people, as well as the potential efficacy of trauma-informed substance use interventions that address IPV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.